|
May 25
|
Bristol Myers Squibb to Present First Results at ASCO and EHA from Phase 3 COMMANDS Study of Reblozyl® (luspatercept-aamt) in First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)
|
|
May 25
|
Mirati's (MRTX) Sitravatinib Fails Lung Cancer Study, Stock Down 8%
|
|
May 25
|
Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under Evaluation in Phase 3 Librexia Program: Ischemic Stroke, Acute Coronary Syndrome and Atrial Fibrillation
|
|
May 25
|
14 Best Biotech Stocks To Buy According To Hedge Funds
|
|
May 24
|
14 Best Healthcare Dividend Stocks to Buy
|
|
May 23
|
Bristol Myers (BMY) Reports Pulmonary Fibrosis Study Results
|
|
May 22
|
Bristol Myers Squibb’s Investigational LPA1 Antagonist Reduces the Rate of Lung Function Decline in Patients with Idiopathic Pulmonary Fibrosis
|
|
May 20
|
Bristol-Myers Squibb (NYSE:BMY) sheds 3.3% this week, as yearly returns fall more in line with earnings growth
|
|
May 19
|
1 Dirt Cheap Dividend Stock to Buy in May
|